Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 35 out of 100. Health systems and care delivery

Topic: Risk, prevention and care in population studies

Plain-language summary

Through 2022, 5% of fee-for-service beneficiaries with dementia received CACP compared to 3% of MA beneficiaries (p < 0.001). We observed a high denial rate for CACP fee-for-service claims (7%). MA enrollees who received CACP were more likely to be enrolled in preferred provider organization plans (46% vs. 37%, p < 0.001). In 2022, primary care physicians accounted for the plurality of CACP-adopting providers (49% of providers, 40% of visits). Neurologists accounted for a disproportionately high share of CACP visits in the same year (11% of total providers, 20% of total visits). CACP delivery remained low despite annual growth in CACP adoption during our study period. Payment incentives in MA, drivers of payment denial in fee-for-service, and dissemination and implementation strategies warrant further exploration.

What this study adds

Evidence grade: Low

This study found that use of Medicare's cognitive assessment and care plan services remained low among beneficiaries with dementia through 2022. It does not address treating, curing, or preventing Alzheimer's disease.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Mulcahy, J., Amjad, H., Gaugler, J. E., Huckfeldt, P. J., & Neprash, H. T. (2026). Adoption of Medicare's Cognitive Assessment and Care Plan Services Benefit: People, Plans, Payment, and Providers. Journal of the American Geriatrics Society. https://doi.org/10.1111/jgs.70617

Vancouver

Mulcahy J, Amjad H, Gaugler JE, Huckfeldt PJ, Neprash HT. Adoption of Medicare's Cognitive Assessment and Care Plan Services Benefit: People, Plans, Payment, and Providers. Journal of the American Geriatrics Society. 2026. doi:10.1111/jgs.70617. PMID: 42524891.

BibTeX

@article{mulcahy2026-42524891,
  author  = {Mulcahy, John and Amjad, Halima and Gaugler, Joseph E. and Huckfeldt, Peter J. and Neprash, Hannah T.},
  title   = {{Adoption of Medicare's Cognitive Assessment and Care Plan Services Benefit: People, Plans, Payment, and Providers}},
  journal = {Journal of the American Geriatrics Society},
  year    = {2026},
  doi     = {10.1111/jgs.70617},
  pmid    = {42524891},
  url     = {https://doi.org/10.1111/jgs.70617}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Why it matters

This study found that use of Medicare's cognitive assessment and care plan services remained low among beneficiaries with dementia through 2022. It does not address treating, curing, or preventing Alzheimer's disease.

Study details

How this study scored 35/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 3 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 5 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited 0 of 7; Citations per year 0 of 5; Impact for its field and year 0 of 6; Cited by studies here 0 of 6; Still being cited 0 of 4; Senior author's track record 2 of 4; Institution's track record 2 of 3; Multicenter collaboration 1 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 35 of 100.35 of 100 points earned65 not earned

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Journal of the American Geriatrics Society)
Journal's citation record 3 / 4 Journal of the American Geriatrics Society: journal h-index 344 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 5 / 5 2026 — within 1 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 0 / 7 Cited 0 times (OpenAlex, 2026-10-10)
Citations per year 0 / 5 0.0 citations a year over 2 year(s) since 2026
Impact for its field and year 0 / 6 Cited 0.0× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 0 / 4 Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 2 / 4 Last-listed author Hannah T. Neprash: h-index 22 (OpenAlex, whole career)
Institution's track record 2 / 3 Johns Hopkins University: institution h-index 2,306 (OpenAlex)
Multicenter collaboration 1 / 3 OpenAlex lists 3 institution(s) in 1 country
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 42524891)
Free to read 2 / 2 Free to read
Total 35 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Related studies in Health systems and care delivery from nearby years

Also tagged “controlled”

1,116 studies in the library carry the topic tag “controlled”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,116 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Health systems and care delivery

See all studies in Health systems and care delivery →